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Abstract
Background: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis,
and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients
with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action
study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Results of
the original mechanism of action study have been published. Peripheral blood was collected at the start of this
clinical trial, and a prior analysis demonstrated that gene expression in PBMCs differed between responders and
non-responders, however, the analysis performed could not be used to predict response.
Methods: Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response
classifier. We used a discriminant analysis method that performs sample classification from gene expression data,
via “nearest shrunken centroid method”. Centroids are the average gene expression for each gene in each class
divided by the within-class standard deviation for that gene.
Results: A disease response classifier using 23 genes was created to accurately predict response to alefacept
(12.3% error rate). While the genes in this classifier should be considered as a group, some of the individual genes
are of great interest, for example, cAMP response element modulator (CREM), v-MAF avian musculoaponeurotic
fibrosarcoma oncogene family (MAFF), chloride intracellular channel protein 1 (CLIC1, also called NCC27), NLR
family, pyrin domain-containing 1 (NLRP1), and CCL5 (chemokine, cc motif, ligand 5, also called regulated upon
activation, normally T expressed, and presumably secreted/RANTES).
Conclusions: Although this study is small, and based on analysis of existing microarray data, we demonstrate that
a treatment response classifier for alefacept can be created using gene expression of PBMCs in psoriasis. This
preliminary study may provide a useful tool to predict response of psoriatic patients to alefacept.
Background
Developing biomarkers that predict response to therapy
is an ambitious goal of modern medicine. This is an
aspect of personalized medicine that could transform
our ability to treat patients successfully with a particular
therapy in a cost-effective manner. Alefacept, an anti-
CD2 fusion protein (Amevive, Astellas Pharma), is a bio-
logic agent that often induces a remarkably durable
remission [1]. However, it produces a PASI 75 response
(Psoriasis Area and Severity Index [PASI] response of
greater than 75% improvement from baseline) in only
approximately 30-50% of patients. Thus alefacept is an
excellent example of a treatment that would benefit
from being able to predict which patients with psoriasis
would respond to this agent, and which patients might
not respond.
The results of our original mechanism of action study
of alefacept have already been published [2,3]. In brief,
patients were classified as histologic responders or non-
responders, as described in the Methods section.
Patients that responded to alefacept showed reductions
in tissue gene expression of IFNg, signal transducer and
activator of transcription 1 (STAT-1), monokine
induced by IFNg (MIG), inducible NO synthase (iNOS),
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alefacept bound primarily to T cells and not DCs, we
suggested that T cells were the primary target for ther-
apy, but that DCs and a spectrum of type 1 inflamma-
tory genes were coordinately suppressed. Furthermore,
we demonstrated by FACS of PBMCs that in all
patients, alefacept treatment caused a preferential





+ T effector memory cells. In
contrast, central memory T cells (CCR7
+CD45RA
-) were
less affected, and naïve T cells (CCR7
+CD45RA
+)w e r e
relatively spared. Circulating CD8
+ effector T cells and
Type 1 T cells (IFN-g-producing) were also significantly
reduced [2,3].
The primary mechanism of action of alefacept is consid-
ered to be by killing CD2
+ T cells by a cytotoxic mechan-
ism (involving NK cell bridging), or by blocking CD2
signaling [4,5]. In a previous study [6], our group estab-
lished a new therapeutic mechanism for alefacept in psor-
iasis, as it also serves as an agonist for CD2 and induces
positive T cell signaling responses. In this study, we ana-
lyzed genomic expression of circulating PBMCs, compar-
ing baseline versus 24 hour time-point. During the first
day of treatment in PBMCs, there was suppression of
inflammatory genes, but perhaps surprisingly, a marked
induction of mRNAs for STAT1, IL-8, and MIG. These
agonistic effects of alefacept in PBMC were confirmed in
vitro. These data demonstrated that alefacept activates
gene expression in leukocytes and suggested that its thera-
peutic action may be as a mixed agonist/antagonist.
These findings suggested that differential activation of
genes may categorize clinical responders to alefacept,
and gave the first indication of differences in the pre-
treatment circulating leukocytes in responders and non-
responders. Thus these results led us to ask whether
baseline gene expression in PBMCs might be used to
classify responders versus non-responders and predict a
priori who would respond to alefacept. This would have
a dual benefit, allowing those responders to receive
treatment with confidence, and sparing those who
would not respond the cost, potential serious immuno-
suppressive effects and inconvenience of a course of
therapy. The aim of this study was to mine our existing
genomic data using alternative, previously developed
analytic methods to generate a “genomic classifier” [7], a
set of genes that could specifically predict response to
alefacept. This “genomic classifier” could then be tested
in a prospective clinical trial of alefacept in psoriasis.
Genomic expression profiles have been successfully
used for disease classification and to predict response to
treatment. In a seminal paper in 1999, Golub et al
demonstrated that the type of haematological malig-
nancy could be determined by class prediction using
microarray data [8]. Since then, other investigators have
shown that genomic patterns of expression could be
used to predict the progression and prognosis of cancer
[9]. Gene expression profiling of neoplastic tissue has
been performed to develop a genomic classifier for
response to a chemotherapy regimen for patients with
advance colorectal cancer [10], or doxorubicin sensitivity
in gastric cancers [11]. Genomic classifiers have also
been developed in breast cancer to predict tamoxifen-
resistance [12], and docetaxel response [13]. In chronic
inflammation such as rheumatoid arthritis, response to
etanercept (Enbrel, TNF-inhibitor) could be predicted
by a genomic classifier consisting of specific combina-
tions of gene doublets and triplets [14].
Methods
Clinical trial
An IRB-approved clinical trial was conducted at Rocke-
feller University in 2002-2003, treating 22 patients with
moderate-to-severe psoriasis with alefacept (7.5-mg
weekly i.v. ×12 weeks). The initial aim of the clinical
trial was to conduct a mechanism of action study, and
the study was powered to produce groups of at least six
patients that could be designated as responders versus
non-responders (as defined below) to alefacept. Patients
were recruited from local dermatologists, and by IRB-
approved radio and print advertisements. 19 males and
3 females, (ages 29-68 years, median 49 years) were
enrolled. Major inclusion criteria were: involvement of
psoriasis vulgaris of >10% body surface area, no systemic
treatment for at least 4 weeks before entering the study,
no significant infections or immunosuppression, and no
significant renal, hepatic, or other medical disease.
Informed consent was obtained. The results of tissue
analysis and peripheral blood analysis describing the
mechanism of action of this biologic agent have already
been published [2,3], and are discussed in the Back-
ground section.
Tissue samples were collected before and during the
trial at baseline (non-lesional and lesional), week 2,
week 6 and week 13. The patients were categorized as
responders or non-responders based on histological
changes in their skin biopsies over the course of the
clinical trial (Figure 1) [2]. Histological response of psor-
iatic lesions was defined as normalization of keratin 16
(K16) expression, reduction of epidermal hyperplasia,
restoration of a granular layer, and orthokeratosis in
week-13 biopsies. Overall, 22 patients were enrolled, 2
dropped out due to non-response. 12 patients were clas-
sified as responders, and 10 as non-responders (8
patients were categorized as non-responders based on
histological analysis, 10 patients were non-responders
based on intent-to-treat). High quality microarray data
were available on 9 responders and 7 non-responders.
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Initial microarray data from PBMCs of these patients
has been published [6]. Briefly, peripheral blood draws
were taken before alefacept administration. PBMCs were
isolated and stored at -80°C, until required. Pre-treat-
ment RNA was extracted, and hybridized to HGU95Av2
Affymetrix Gene Chip containing probe sets represent-
ing 12,000 genes, using standard methods.
Quality Control, Pre-processing and Filtering
Gene Chip CEL files were scrutinized for spatial arte-
facts using Harshlight package https://mustat.rockefeller.
edu/harshlight[15]. Intensity values (CEL files) were pre-
processed to obtained expression values using GCRMA
algorithm. Expression values were filtered to eliminate
probe sets with low variation or low intensity. Probe
sets with standard deviation greater than 0.3, and
expression values greater than 3 in at least 1 sample,
were kept for further analysis, leaving a total of 5218
probe sets. Genes were annotated using up-to date
annotation from of HGU95av2 chips available at Bio-
conductor. The data discussed in this publication have
been deposited in NCBI’sG e n eE x p r e s s i o nO m n i b u s
and are accessible through GEO Series accession num-
ber (GSE18948).
Discriminant Analysis
We used a discriminant analysis method that performs
sample classification from gene expression data, via
“nearest shrunken centroid method” [7]. This method is
a modification of the conventional nearest centroid
method [16], where centroids for each gene (average
gene expression for the gene in each class) are divided
by the within-class standard deviation in order to give
more weight to genes with smaller variations across
samples in the same class. Then, for prediction, every
new sample is classified based on the gene expression
profile of the sample by the following prediction rule:
The class whose centroid is closest (by euclidean dis-
t a n c e )t ot h eg e n ee x p r e s s i o np r o f i l eo ft h es a m p l ei s
the predicted class for that new sample.
Nearest shrunken centroid classification makes one
important modification to conventional nearest centroid
classification. It “shrinks” each of the class centroids
toward the overall centroid for all classes by an amount
called the “threshold”. This shrinkage consists of moving
the centroid towards zero by threshold, setting it equal
to zero if it hits zero: i.e if threshold = 2, a centroid of
3.2 would be shrunk to 1.2 and a centroid of 1.2 would
be shrunk to zero. After shrinking the centroids, the
new sample is classified by the prediction rule of the
nearest centroid method (see above), but using the
shrunken class centroids. This method has two advan-
tages: it can make the classifier more accurate by redu-
cing the effect of noisy genes, and it performs automatic
gene selection. If a gene is shrunk to zero for all classes,
then it is eliminated from the classifier. Alternatively, it
may be set to zero for all classes except one, indicating
that high or low expression for that gene characterizes
that class.
The value of the threshold (which determines the
number of genes in the final classifier) is set by the user
Figure 1 Histological classification of response. Clinical photographs, haematoxylin and eosin (H&E) and keratin 16 staining of non-lesional
skin, and lesional skin pre and post alefacept treatment in (A) a responding patient and (B) a non-responding patient. Lesional skin in both
patients demonstrated characteristic features of psoriasis: epidermal acanthosis, parakeratosis, loss of the granular layer, elongation of the rete,
dilated blood vessels, and a dense inflammatory infiltrate in the dermis. There was strong K16 staining. Only the responding patient showed
resolution of inflammation and K16 staining to non-lesional appearance.
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this study, we used 7-fold cross validation to assess the
misclassification error (Figure 2A) and the resulting
false discovery rate (FDR) for the genes in the classifier
( F i g u r e2 B ) .T h ev a l u eo ft h et h r e s h o l dw a ss e tt ot h e
value that minimized both statistics (Figure 2A and 2B).
Once the classifier is built (by establishing the genes
involved the prediction rule), the probability of being
classified in each class can be calculated for each sam-
ple/patient (Figure 2C). The package pamr from R
http://www.R-project.org/ was used to perform this ana-
lysis. There is insufficient RNA remaining from this trial
to conduct confirmative PCR experiments.
Results and Discussion
The age, gender and ethnicity of the patients, as well as
PASI scores during the trial are described in Table 1.
An example of the clinical photography, histology and
K16 immunohistochemistry for a responding (Figure
1A) and a non-responding patient (Figure 1B) are
demonstrated. Lesional skin of responding patients
showed epidermal acanthosis, parakeratosis, loss of the
granular layer, elongation of the rete, dilated blood ves-
sels, and a dense inflammatory infiltrate in the dermis.
There was strong K16 staining throughout the epider-
mis. In responding patients, at the end of treatment
there was resolution of cutaneous inflammation almost
Figure 2 Determining the genomic classifier by discriminant analysis. (A) The misclassification error (y-axis) as a function of the threshold
(x-axis) and the number of genes (top x-axis). The red arrow identifies the optimal threshold (2.25), which gave an overall error rate of 0.123. (B)
Median and 90th percentile of the false discovery rate (FDR, y-axis) as a function of threshold (top x-axis), and number of genes (x-axis). The red
arrow identifies the optimal threshold (2.25). (C) The posterior probability of the patients in our trial being classified as a non-responder (<0.5,
red) or a responder (>0.5, blue). Patients 1-7 were histological non-responders, and patients 8-16 were responders. Two patients 6 and 7 were
mis-identified by the classifier as responders when they were histological non-responders.
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different in the non-responding patients, as the histology
of the psoriasis plaque and K16 immuno-staining at the
end of treatment were similar to lesional skin the begin-
ning of the trial.
Microarray data on 9 responders and 7 non-respon-
ders were available for further analysis using the discri-
minant analysis method. Figure 2 shows the
misclassification error rate (Figure 2A) and the false dis-
covery rate (Figure 2B) for thresholds ranging from 0-3.
A threshold of 2.25 was chosen to create the final pre-
dictor (red arrow), as it rendered the best performance
of the classifier in the cross-validation stage. The error
rate for this final predictor was 0.123 (12.3%), as two
non-responder patients were incorrectly classified as
responders (patients 6 and 7, Figure 2C). However, the
classifier correctly identified all responders as respon-
ders (patients 8-16). Classifying a responder as a non-
responder would be the most costly error in terms of
patient treatment, because otherwise a potential respon-
der patient would be incorrectly left without treatment.
However, this is still an improvement over the current
situation as clinicians try to decide which therapeutic
agent is best for a given patient. Approximately four out
of ten patients would respond to alefacept (given a 30-
50% therapeutic response rate); if this predictor is vali-
dated with the same error rate (12.3%), approximately
five out of six patients would respond to alefacept. The
false discovery rate for this final predictor was smaller
than 0.1 (Figure 2B).
With this threshold 23 genes were selected to form
the classifier that predict response to alefacept using
these pre-treatment blood measurements (Table 2). Fig-
ure 3 shows the centroids of each gene in both respon-
ders and non-responder groups. A more stringent cut-
off (threshold of 2.3) gave fewer genes (no. of genes =
19). However, while some genes appear to separate
more clearly, we would like to use all 23 genes in a
future prediction trial, as it makes it less likely to over-
look genes that could be important.
It is important to acknowledge the limitations of our
study. The data-base for this study was small, as we
were restricted to the clinical trial sample size, and the
number of patients with good quality RNA and chip
data. Although this data has been previously analyzed to
find genes that were differentially expressed between
responders and non-responders, this time we asked a
different question of the data, specifically, could genes
expressed in PBMCs before treatment predict response
to alefacept. While we note that two of the non-
responding patients were misclassified as responders,
our preliminary conclusions suggest that this is a pro-
mising approach.
The genes in this classifier should be considered as a
group. However some of the individual genes are of
great interest. For example, cAMP response element
modulator (CREM) is a gene that is highly increased in
responders compared to non-responders, and this
encodes activators and antagonists of camp-inducible
transcription by differential splicing [17]. In systemic
lupus erythematosis, phosphorylated CREM correlated
with decreased production of IL-2 and anergy in T cells
[18]. The pattern of expression of v-MAF avian muscu-
loaponeurotic fibrosarcoma oncogene family (MAFF) is
Table 1 Demographic details and PASI scores for patients used to develop genomic classifier to alefacept.
Patients Age Gender Ethnicity Response PASI Baseline PASI End of treatment
1 33 M Caucasian NR 6.1 4.3
2 52 M Caucasian NR 6.8 5.3
3 49 M Hispanic NR 23.0 19.4
4 59 M Caucasian NR 43.2 32.2
5 59 M Caucasian NR 17.7 *NA
6 55 M Caucasian NR 34.3 22.8
7 38 M Caucasian NR 9.3 4.7
8 49 M Caucasian R 10.9 2.7
9 43 M Caucasian R 26.1 19.3
10 45 M African American R 17.1 2.2
11 36 M Asian R 17.1 2.3
12 44 M Hispanic R 35.0 5.2
13 41 M Caucasian R 20.7 5.9
14 68 M Caucasian R 17.1 14.4
15 62 M Caucasian R 9.4 3.8
16 29 F Hispanic R 16.8 2.0
* Little clinical improvement after 10 weeks of treatment; PASI difficult to determine due to skin infection.
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32067_at CREM cAMP responsive element modulator 1390 2.71 1.00
36711_at MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 23764 2.86 1.00
36131_at CLIC1 chloride intracellular channel 1 1192 4.71 1.00
40296_at SASH3 SAM and SH3 domain containing 3 54440 11.71 0.86
36909_at WEE1 WEE1 homolog (S. pombe) 7465 11.29 0.86
41122_at AOF2 amine oxidase (flavin containing) domain 2 23028 14.86 1.00
32317_s_at SULT1A3 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 6818 14.14 0.71
1309_at PSMB3 proteasome (prosome, macropain) subunit, beta type, 3 5691 15.14 0.57
35980_at PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) 23236 18.71 0.71
31804_f_at SULT1A1 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 6817 17.29 0.71
37127_at NLRP1 NLR family, pyrin domain containing 1 22861 16.86 0.86
37029_at ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (oligomycin
sensitivity conferring protein)
539 18.86 0.57
37417_at POU2F2 POU class 2 homeobox 2 5452 20.86 0.71
35083_at FTL ferritin, light polypeptide 2512 20.86 0.57
1404_r_at CCL5 chemokine (C-C motif) ligand 5 6352 25.43 0.57
34279_at NBPF10 neuroblastoma breakpoint family, member 10 440673 35.14 0.43
38791_at DDOST dolichyl-diphosphooligosaccharide-protein glycosyltransferase 1650 24 0.57
35823_at PPIB peptidylprolyl isomerase B (cyclophilin B) 5479 23.71 0.86
41344_s_at PURA purine-rich element binding protein A 5813 26.29 0.71
464_s_at IFI35 interferon-induced protein 35 3430 34 0.57
39867_at TUFM Tu translation elongation factor, mitochondrial 7284 27.43 0.43
1676_s_at EEF1G eukaryotic translation elongation factor 1 gamma 1937 27.71 0.71
35821_at HDAC3 histone deacetylase 3 8841 29.57 0.43
Figure 3 Centroids for each gene in the classifier. Centroid expression of the 23 genes in the genomic classifier for non-responders (red) and
responders (blue). Lines to the left indicate relative increased levels of expression; lines to the right indicate relative decreased levels of
expression. Some genes, for example the top two CREM and MAFF, are completely opposite in their expression in these two groups (down in
non-responders, up in responders).
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upstream promoter region of the oxytocin receptor
gene, and may be involved in the cellular stress response
[19]. Chloride intracellular channel protein 1 (CLIC1,
also called NCC27) has the opposite expression pattern
with an increase in non-responders, and a decrease in
responders. Although the role of this gene in inflamma-
tion is not entirely clear, this gene does function as a
nuclear chloride channel protein.
NLR family, pyrin domain-containing 1 (NLRP1) is
involved in activation of caspase-1 and caspase-5 as part
of the NALP1 inflammasome complex. The formation
of this complex is important in the processing and
release of bioactive IL-1b and IL-18 [20]. NLRP1 is also
involved in apoptosis. CCL5 (chemokine, cc motif,
ligand 5, also called regulated upon activation, normally
T expressed, and presumably secreted/RANTES) is a
chemo-attractant for circulating monocytes, memory T
helper cells, and eosinophils [21]. Thus there were sev-
eral interesting genes in this list, although the list should
be taken as a whole for its use as a genomic classifier.
Conclusion
We conducted an alternative analysis of our previously
published baseline peripheral blood microarray data [6],
in order to determine the genes that would predict
response to alefacept. We used a discriminant analysis
method that performs sample classification from gene
expression data [7]. The database for this study was
small, limited by the sample size of the clinical trial, and
makes our conclusions preliminary. This approach and
data are presented to show how pre-treatment periph-
eral blood microarray data can be used to identify a
novel set of genes and develop a “genomic classifier”.
This genomic classifier could predict response to treat-
ment and thus help physicians in selecting psoriasis
patients who could benefit from treatment with Alefa-
cept. This genomic classifier now needs to be tested
prospectively.
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